WEBULL
News
ABVX
114.51
+3.50%
3.87
Optimistic Buy Rating for Abivax SA: Potential of Obefazimod Amid Safety and Financial Considerations
TipRanks · 2d ago
Weekly Report: what happened at ABVX last week (1124-1128)?
Weekly Report · 5d ago
SA Quant ranks Goldman's health care stocks with biggest increase in hedge fund popularity
Seeking Alpha · 11/25 21:19
Truist Securities Initiates Coverage On Abivax with Buy Rating, Announces Price Target of $140
Benzinga · 11/24 17:47
Abivax SA Sponsored ADR (ABVX) Receives a New Rating from Truist Financial
TipRanks · 11/24 12:25
Weekly Report: what happened at ABVX last week (1117-1121)?
Weekly Report · 11/24 09:32
Which of Goldman's hedge fund favorites is the best buy, as per SA Quant ratings?
Seeking Alpha · 11/22 16:14
Goldman's 50 stocks that matter most to hedge funds
Seeking Alpha · 11/21 14:42
Abivax gains amid takeover speculation
Seeking Alpha · 11/20 16:37
Weekly Report: what happened at ABVX last week (1110-1114)?
Weekly Report · 11/17 09:32
Abivax SA Sponsored ADR (ABVX) Upgraded to Buy: Here's What You Should Know
NASDAQ · 11/13 17:00
Are Medical Stocks Lagging Abivax SA Sponsored ADR (ABVX) This Year?
NASDAQ · 11/13 14:40
Weekly Report: what happened at ABVX last week (1103-1107)?
Weekly Report · 11/10 09:31
Abivax: Phase 3 Data Was A Home Run, Top Target For M&A In 2026
Seeking Alpha · 11/08 12:57
Caterpillar upgraded, Elf Beauty downgraded: Wall Street’s top analyst calls
TipRanks · 11/06 14:51
This Brinker International Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Benzinga · 11/06 13:34
Wolfe Research Initiates Coverage On Abivax with Outperform Rating, Announces Price Target of $176
Benzinga · 11/06 13:22
Kepler Capital Reaffirms Their Buy Rating on Abivax SA (0RA9)
TipRanks · 11/06 01:47
Positive Outlook for Abivax SA: Obefazimod’s Potential in Crohn’s Disease Drives Buy Rating
TipRanks · 11/05 21:45
Abivax initiated with an Outperform at Wolfe Research
TipRanks · 11/05 21:41
More
Webull provides a variety of real-time ABVX stock news. You can receive the latest news about Abivax S.A. through multiple platforms. This information may help you make smarter investment decisions.
About ABVX
Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.